Compare Stocks: PBM, SCYX, DWTX, and RYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$1.49 +2.1%	$1.92	$1.28 ▼ $7.20	$50.68M	1.92	76,016 shs	30,849 shs
PBM Psyence Biomedical	$5.40 +4.6%	$4.53	$1.92 ▼ $28.13	$12.32M	1.68	958,255 shs	63,007 shs
RYM RYTHM	$19.46 -0.7%	$21.99	$14.00 ▼ $53.65	$42.42M	9.46	14,814 shs	1,459 shs
SCYX SCYNEXIS	$4.89 -4.6%	$4.88	$3.53 ▼ $9.12	$48.67M	1.06	136,680 shs	129,151 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	0.00%	+7.35%	-36.24%	+5.80%	-77.22%
PBM Psyence Biomedical	0.00%	-7.19%	+13.66%	+68.63%	-74.36%
RYM RYTHM	0.00%	-11.03%	-23.77%	-19.28%	-54.32%
SCYX SCYNEXIS	0.00%	+16.63%	-3.40%	+8.25%	-20.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$1.49 +2.1%	$1.92	$1.28 ▼ $7.20	$50.68M	1.92	76,016 shs	30,849 shs
PBM Psyence Biomedical	$5.40 +4.6%	$4.53	$1.92 ▼ $28.13	$12.32M	1.68	958,255 shs	63,007 shs
RYM RYTHM	$19.46 -0.7%	$21.99	$14.00 ▼ $53.65	$42.42M	9.46	14,814 shs	1,459 shs
SCYX SCYNEXIS	$4.89 -4.6%	$4.88	$3.53 ▼ $9.12	$48.67M	1.06	136,680 shs	129,151 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	0.00%	+7.35%	-36.24%	+5.80%	-77.22%
PBM Psyence Biomedical	0.00%	-7.19%	+13.66%	+68.63%	-74.36%
RYM RYTHM	0.00%	-11.03%	-23.77%	-19.28%	-54.32%
SCYX SCYNEXIS	0.00%	+16.63%	-3.40%	+8.25%	-20.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DWTX Dogwood Therapeutics	2.00	Hold	$12.00	705.37% Upside
PBM Psyence Biomedical	1.00	Sell	N/A	N/A
RYM RYTHM	1.00	Sell	N/A	N/A
SCYX SCYNEXIS	2.33	Hold	$33.00	575.54% Upside

Current Analyst Ratings Breakdown

Latest PBM, SCYX, DWTX, and RYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	RYM RYTHM	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	DWTX Dogwood Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/24/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	PBM Psyence Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	$7.39 per share	N/A
RYM RYTHM	$17.28M	2.46	N/A	N/A	$6.06 per share	3.21
SCYX SCYNEXIS	$20.60M	2.36	N/A	N/A	$9.07 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DWTX Dogwood Therapeutics	-$34.26M	-$8.95	N/A	N/A	N/A	N/A	-75.55%	-40.28%	11/5/2026 (Estimated)
PBM Psyence Biomedical	-$6.94M	$25.34	0.21	N/A	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	-$33.26M	-$10.53	N/A	N/A	N/A	-6.20%	-12.57%	-2.60%	N/A
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	N/A	-44.15%	-32.61%	11/4/2026 (Estimated)

Latest PBM, SCYX, DWTX, and RYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	DWTX Dogwood Therapeutics	-$0.14	-$0.34	-$0.20	-$0.34	N/A	N/A
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million
8/4/2026	Q2 2026	RYM RYTHM	N/A	$0.09	N/A	$0.09	N/A	$23.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DWTX Dogwood Therapeutics	N/A	3.89	3.89
PBM Psyence Biomedical	N/A	14.62	14.62
RYM RYTHM	N/A	0.59	0.56
SCYX SCYNEXIS	N/A	9.65	9.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DWTX Dogwood Therapeutics	9.05%
PBM Psyence Biomedical	77.44%
RYM RYTHM	5.98%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
DWTX Dogwood Therapeutics	0.30%
PBM Psyence Biomedical	3.60%
RYM RYTHM	3.48%
SCYX SCYNEXIS	4.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DWTX Dogwood Therapeutics	8	33.99 million	33.89 million	N/A
PBM Psyence Biomedical	12	2.29 million	2.21 million	N/A
RYM RYTHM	141	2.18 million	2.10 million	N/A
SCYX SCYNEXIS	29	9.95 million	9.54 million	Optionable

PBM, SCYX, DWTX, and RYM Headlines

Recent News About These Companies

Contrasting Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)

October 2 at 5:59 AM | americanbankingnews.com

SCYNEXIS Secures BARDA Funding for Antifungal Pipeline

September 30, 2026 | theglobeandmail.com

SCYNEXIS Secures BARDA Funding for Antifungal Pipeline

September 30, 2026 | theglobeandmail.com

SCYNEXIS, Inc. (NASDAQ: SCYX) Wins $18.5 Million for Antifungal

September 30, 2026 | americanbankingnews.com

Scynexis stock surges on $214M BARDA contract for SCY-247

September 28, 2026 | finance.yahoo.com

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract

September 28, 2026 | finance.yahoo.com

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

September 28, 2026 | globenewswire.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

September 22, 2026 | markets.businessinsider.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

September 22, 2026 | globenewswire.com

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

September 15, 2026 | globenewswire.com

SCYNEXIS Names Sanjay Subramanian as CFO

September 10, 2026 | finance.yahoo.com

Scynexis Names Sanjay Subramanian CFO

September 10, 2026 | rttnews.com

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average - Here's What Happened

September 9, 2026 | marketbeat.com

SCYNEXIS to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026 | globenewswire.com

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | tmcnet.com

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 30, 2026 | globenewswire.com

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

June 26, 2026 | tipranks.com

SCYNEXIS Inc.

June 24, 2026 | marketwatch.com

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM, SCYX, DWTX, and RYM Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

$1.49 +0.03 (+2.05%)

As of 10:57 AM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Psyence Biomedical NASDAQ:PBM

$5.40 +0.24 (+4.61%)

As of 10:56 AM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

RYTHM NASDAQ:RYM

$19.46 -0.14 (-0.71%)

As of 10:56 AM Eastern

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

SCYNEXIS NASDAQ:SCYX

$4.88 -0.24 (-4.59%)

As of 10:56 AM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBM, SCYX, DWTX, and RYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBM, SCYX, DWTX, and RYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBM, SCYX, DWTX, and RYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM, SCYX, DWTX, and RYM Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Psyence Biomedical NASDAQ:PBM

RYTHM NASDAQ:RYM

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBM, SCYX, DWTX, and RYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBM, SCYX, DWTX, and RYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBM, SCYX, DWTX, and RYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM, SCYX, DWTX, and RYM Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Psyence Biomedical NASDAQ:PBM

RYTHM NASDAQ:RYM

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools